Cargando…
Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evalua...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558323/ https://www.ncbi.nlm.nih.gov/pubmed/35083494 http://dx.doi.org/10.2340/actadv.v102.1087 |
_version_ | 1784807416101076992 |
---|---|
author | FRANCESCHI, Joséphine EHRET, Marine VISSEAUX, Laetitia DURLACH, Anne BARBE, Coralie DUROT, Éric GRANGE, Florent |
author_facet | FRANCESCHI, Joséphine EHRET, Marine VISSEAUX, Laetitia DURLACH, Anne BARBE, Coralie DUROT, Éric GRANGE, Florent |
author_sort | FRANCESCHI, Joséphine |
collection | PubMed |
description | Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n = 48), Sézary syndrome (n = 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (n = 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥ 2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16–101 months. |
format | Online Article Text |
id | pubmed-9558323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-95583232022-10-20 Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas FRANCESCHI, Joséphine EHRET, Marine VISSEAUX, Laetitia DURLACH, Anne BARBE, Coralie DUROT, Éric GRANGE, Florent Acta Derm Venereol Original Article Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n = 48), Sézary syndrome (n = 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (n = 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥ 2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16–101 months. Society for Publication of Acta Dermato-Venereologica 2022-03-22 /pmc/articles/PMC9558323/ /pubmed/35083494 http://dx.doi.org/10.2340/actadv.v102.1087 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Original Article FRANCESCHI, Joséphine EHRET, Marine VISSEAUX, Laetitia DURLACH, Anne BARBE, Coralie DUROT, Éric GRANGE, Florent Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas |
title | Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas |
title_full | Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas |
title_fullStr | Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas |
title_full_unstemmed | Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas |
title_short | Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas |
title_sort | survival and prognostic factors in patients with aggressive cutaneous t-cell lymphomas |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558323/ https://www.ncbi.nlm.nih.gov/pubmed/35083494 http://dx.doi.org/10.2340/actadv.v102.1087 |
work_keys_str_mv | AT franceschijosephine survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas AT ehretmarine survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas AT visseauxlaetitia survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas AT durlachanne survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas AT barbecoralie survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas AT duroteric survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas AT grangeflorent survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas |